NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$17.62

-0.04 (-0.23 %)

(As of 07/28/2021 12:00 AM ET)

Add

Compare

Today's Range

$17.10

▼

$18.10

50-Day Range

$16.65

▼

$21.15

52-Week Range

$11.61

▼

$21.64

Volume143,211 shs

Average Volume150,771 shs

Market Capitalization$662.39 million

P/E RatioN/A

Dividend YieldN/A

Beta1.26

30 days | 90 days | 365 days | Advanced Chart

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Sells 5,000 Shares of Stock
July 27, 2021 | americanbankingnews.com

Brokerages Expect Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Will Post Earnings of -$0.60 Per Share
July 27, 2021 | americanbankingnews.com

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 6.2%
July 26, 2021 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Matthew K. Fust Sells 5,000 Shares
July 20, 2021 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Buy" from Brokerages
July 17, 2021 | americanbankingnews.com

Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
July 16, 2021 | finance.yahoo.com

How Much Are Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insiders Taking Off The Table?
July 12, 2021 | nasdaq.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Forecasted to Earn Q1 2022 Earnings of ($0.62) Per Share
July 12, 2021 | americanbankingnews.com

Zacks: Analysts Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to Announce -$0.60 Earnings Per Share
July 5, 2021 | americanbankingnews.com

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
June 28, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.crinetics.com
Phone858-450-6464
Employees93
Year FoundedN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales9,462.70
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.13 per share
Price / Book3.43

Profitability

EPS (Most Recent Fiscal Year)($2.42)
Net Income$-73,810,000.00
Net MarginsN/A
Return on Equity-44.81%
Return on Assets-41.52%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares37,593,000
Market Cap$662.39 million
Next Earnings Date8/6/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.65 out of 5 stars

Medical Sector

790th out of 2,210 stocks

Pharmaceutical Preparations Industry

391st out of 867 stocks

3.5 Analyst's Opinion

Consensus Rating
Crinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.25, Crinetics Pharmaceuticals has a forecasted upside of 105.7% from its current price of $17.62.
Amount of Analyst Coverage
Crinetics Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
Crinetics Pharmaceuticals has received 93 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Crinetics Pharmaceuticals has received 55 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Crinetics Pharmaceuticals has received 62.84% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Crinetics Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Crinetics Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,000.00 in company stock.
Percentage Held by Insiders
Only 7.40% of the stock of Crinetics Pharmaceuticals is held by insiders.
Percentage Held by Institutions
81.64% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($2.58) to ($2.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Crinetics Pharmaceuticals is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Crinetics Pharmaceuticals is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Crinetics Pharmaceuticals has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Crinetics Pharmaceuticals?

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Crinetics Pharmaceuticals.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings results on Thursday, May, 6th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.03.
View Crinetics Pharmaceuticals' earnings history.

How has Crinetics Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX stock has increased by 13.7% and is now trading at $17.62.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CRNX?

5 brokerages have issued 1-year price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $42.00. On average, they anticipate Crinetics Pharmaceuticals' stock price to reach $36.25 in the next year. This suggests a possible upside of 105.7% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:

Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 59, Pay $820.33k)
Mr. Marc J. C. Wilson, CFO & Sec. (Age 42, Pay $527.72k)
Dr. Ajay Madan DABT, Ph.D., D.A.B.T., Chief Devel. Officer (Age 53, Pay $567.53k)
Dr. Yun-Fei Zhu, Founder & VP of Chemistry (Age 58)
Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 55)
Ms. Garlan Adams, Gen. Counsel
Ms. Adriana Cabre, VP of HR
Dr. Alan S. Krasner, Chief Medical Officer (Age 58)
Mr. Peter Trainer BSc, MBChB, M.D., FRCP, VP of Clinical Endocrinology
Ms. Gina Ford M.B.A., R.Ph., RPh, VP of Corp. Strategy & Commercial Planning

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Crinetics Pharmaceuticals' key competitors?

Some companies that are related to Crinetics Pharmaceuticals include Pacira BioSciences (PCRX), Prestige Consumer Healthcare (PBH), Sage Therapeutics (SAGE), OPKO Health (OPK), Insmed (INSM), Verve Therapeutics (VERV), IGM Biosciences (IGMS), ATA (ATAI), Rocket Pharmaceuticals (RCKT), Amicus Therapeutics (FOLD), Arcus Biosciences (RCUS), Corcept Therapeutics (CORT), ALX Oncology (ALXO), Prothena (PRTA) and Zentalis Pharmaceuticals (ZNTL).
View all of CRNX's competitors.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $17.62.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $662.39 million and generates $70,000.00 in revenue each year. The company earns $-73,810,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 93 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here